Several studies reported the nanocarrier-based targeting of the cancer biomarkers such as, transforming growth factor-beta-1 (TGF-β1), transmembrane receptor P185(HER2) for targeted cancer therapy, to our knowledge, none of these studies utilized to target the ROS using antioxidant peptide (Pep-A) (Prades et al. 2012; Tsai et al. 2013; Kodiha et al. 2015). This evidence concerns the gene ERBB2 and cancer.